#Paris #France #VolitionRx #Nu.Q #DETECSEPS

VolitionRx Launches DETECSEPS Program in France

VolitionRx Limited (NYSE AMERICAN: VNRX) recently made headlines with the launch of DETECSEPS, a pivotal initiative aimed at improving the early detection of sepsis, a life-threatening condition often triggered by infection. The project received €6.3 million in funding from the French government and integrates advanced medical research with innovative technology designed to save lives.

Understanding the DETECSEPS Initiative

DETECSEPS stands out as a multi-faceted project initiated by the IHU SEPSIS, recognized as the world’s first medical research center dedicated solely to combatting sepsis. It is coordinated by the Assistance Publique - Hôpitaux de Paris (AP-HP), which collaborates with Hospices Civils de Lyon (HCL) and industry partners including IDS France and VolitionRx.

The project secured its funding through the Challenge Prevention program, part of the broader France 2030 initiative, emphasizing the country’s commitment to health innovation. Notably, VolitionRx will supply its proprietary Nu.Q® NETs assay, which will serve as the sole biomarker for this comprehensive evaluation of sepsis in real-world settings.

Significance of Early Sepsis Detection

According to Professor Djillali Annane, Director of IHU SEPSIS, the launch marks a critical advancement in sepsis management. The primary goal is to accurately identify patients arriving at the emergency department who are at risk of sepsis, thereby ensuring timely medical care is administered to those who need it while safely redirecting others.

This initiative promises not only to enhance patient care but also to alleviate the burdens on emergency services, consequently reducing the socio-economic impact of sepsis, which claims approximately 21 million lives globally each year.

The Role of Nu.Q® NETs Assay

The Nu.Q® NETs assay has been specifically developed to enhance sepsis monitoring, providing healthcare professionals with timely insights. Dr. Andrew Retter, Medical Consultant at VolitionRx, emphasized the assay's integration with the IDS i10® automated analyzer, which is designed to deliver results within an hour. This rapid processing capability could optimize the National Early Warning Score (NEWS) 2, ensuring that the neediest patients receive prompt medical attention.

A Collaborative Effort to Save Lives

The DETECSEPS project is indeed a collaborative effort leveraging various expertise and resources. The consortium includes emergency departments at major AP-HP hospitals, further enhancing its reach and effectiveness in real-time sepsis identification and response.

With nearly 57,000 deaths annual in France attributable to sepsis, the need for reliable detection methods is imperative. Professor Sébastien Beaune, an Emergency Department coordinator and investigator for DETECSEPS, remarked on the project's critical focus: combining routine clinical scores with the Nu.Q® NETs biomarker to accurately assess patients' risks and initiate necessary treatments swiftly.

Future Implications of DETECSEPS

The social and healthcare implications of this program extend beyond France’s borders, indicating a potential for implementation in various countries facing similar challenges with sepsis. Mr. Rémi Rabeuf, VP of Corporate Alliances at Volition, expressed optimism for DETECSEPS, pointing toward the broader applicability of the solutions developed through this project.

As VolitionRx continues to pioneer the integration of epigenetic science into practical healthcare solutions, the DETECSEPS initiative exemplifies its dedication to transforming scientific advancements into actionable strategies, ultimately aiming to save lives and improve quality of care.

In conclusion, the successful launch of the DETECSEPS program heralds a new era in sepsis management and highlights the crucial intertwining of technology, research, and clinical practice. This initiative not only seeks to enhance early detection but also to set a precedent for future innovations in patient care across the globe.